

Supplemental Table. Willingness to temporarily or permanently discontinue medications when receiving the COVID-19 vaccine.

	N	Yes - willing to discontinue n (%)	No - not willing to discontinue n (%)	Not sure n (%)
Systemic glucocorticoids	762	375 (49.2)	246 (32.3)	141 (18.5)
NSAIDs	740	570 (77.0)	94 (12.7)	76 (10.3)
Antimalarials	733	569 (77.6)	65 (8.9)	99 (13.5)
Methotrexate	855	700 (81.9)	59 (6.9)	96 (11.2)
Other csDMARDs*	510	379 (74.2)	60 (11.8)	71 (13.9)
Mycophenolate	228	160 (70.2)	30 (13.2)	38 (16.7)
Other antimetabolites**	21	12 (57.1)	5 (23.8)	4 (19.0)
Abatacept	71	61 (85.9)	4 (5.6)	6 (8.5)
Rituximab	162	110 (67.9)	23 (14.2)	29 (17.9)
TNF inhibitors	493	358 (72.6)	58 (11.8)	77 (15.6)
Other biologics***	206	139 (67.5)	28 (13.6)	39 (18.9)
JAK inhibitors	121	104 (86.0)	10 (8.3)	7 (5.8)
IVIG	102	59 (57.8)	25 (24.5)	18 (17.6)

IL = interleukin; NSAIDs = non-steroidal anti-inflammatory drugs; csDMARDs = conventional synthetic drug modifying antirheumatic drugs; JAK = janus kinase inhibitors; TNF = tumor necrosis factor; IVIG = intravenous immunoglobulin.

IL = interleukin; NSAIDs = non-steroidal anti-inflammatory drugs; JAKi = janus kinase inhibitors; TNF = tumor necrosis factor;

* Includes apremilast, azathioprine, 6-mercaptopurine, leflunomide, sulfasalazine.

** Includes calcineurin inhibitors (cyclosporine, tacrolimus), cyclophosphamide, thalidomide, and lenalidomide.

***Includes belimumab, IL-1 inhibitors (anakinra, canakinumab, riloncept), IL-6 inhibitors (tocilizumab, sarilumab, siltuximab), IL-12/23 inhibitors (ustekinumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab), eculizumab, mepolizumab and vedolizumab.